Compare AUPH & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUPH | PDX |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | Canada | NY |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 904.4M |
| IPO Year | 2014 | N/A |
| Metric | AUPH | PDX |
|---|---|---|
| Price | $14.03 | $21.13 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 928.7K | 134.9K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.95% |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.35 | N/A |
| Revenue Next Year | $15.66 | N/A |
| P/E Ratio | $6.79 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $6.83 | $18.47 |
| 52 Week High | $16.54 | $25.25 |
| Indicator | AUPH | PDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 68.59 |
| Support Level | $13.52 | $20.93 |
| Resistance Level | $15.23 | $22.15 |
| Average True Range (ATR) | 0.46 | 0.37 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 12.59 | 92.32 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.